The landscape of rare sugar production is undergoing a significant transformation, driven by the urgent need for healthier sweetener alternatives that do not compromise on taste or functionality. The GreenLight Biosciences D-psicose biosynthesis patent US portfolio represents a critical milestone in synthetic biology, detailing novel enzymatic pathways and cell-free systems designed to overcome the historical bottlenecks of cost, yield, and scalability that have plagued traditional fermentation and chemical synthesis methods. At the forefront of this shift stands GreenLight Biosciences, a company leveraging its proprietary cell-free biomanufacturing platform to access the commercial potential of D-psicose, also known as D-allulose. This intellectual property not only secures a competitive moat for the company but also signals a broader industry pivot toward sustainable, enzyme-driven manufacturing for high-value food ingredients.
The Strategic Importance of D-Psicose in Modern Nutrition
Before diving into the specifics of the patent claims, it is essential to understand why D-psicose has become a "holy grail" target for biotech innovators. Now, classified as a rare sugar, D-psicose is a C-3 epimer of fructose. It possesses approximately 70% of the sweetness of sucrose but with a near-zero caloric value (0.On top of that, 2–0. That's why 4 kcal/g) and a glycemic index effectively at zero. Worth adding: unlike many high-intensity sweeteners such as stevia or monk fruit, D-psicose offers bulking properties, Maillard reaction participation (browning), and freezing point depression nearly identical to sucrose. This makes it a true drop-in replacement for sugar in formulations ranging from baked goods and ice cream to beverages and confectionery.
Despite its functional superiority, global adoption has been constrained by production economics. Traditional microbial fermentation—using engineered E. coli or Corynebacterium—suffers from low titers, byproduct formation (such as D-sorbitol or D-mannitol), and the metabolic burden placed on the host cell, which often leads to plasmid instability and reduced viability over long fermentation runs. Consider this: chemical synthesis lacks stereoselectivity, creating separation nightmares. Naturally occurring in minute quantities in figs, raisins, and wheat, extraction is commercially unviable. The GreenLight Biosciences D-psicose biosynthesis patent US filings directly address these pain points by bypassing the living cell entirely The details matter here..
Real talk — this step gets skipped all the time.
Deconstructing the Cell-Free Biomanufacturing Platform
The core innovation protected within the US patent portfolio revolves around cell-free metabolic engineering. Consider this: rather than relying on a living microorganism to maintain homeostasis, replicate DNA, and express proteins while simultaneously producing the target metabolite, GreenLight’s platform utilizes a in vitro reaction mixture. This lysate-based system contains only the necessary enzymes, cofactors (NADPH/NADP+, ATP/ADP), and substrates required for the specific biosynthetic pathway It's one of those things that adds up..
The patents describe several key advantages inherent to this approach, which are explicitly claimed as improvements over the prior art:
- Elimination of Cellular Maintenance Burden: In whole-cell fermentation, a significant percentage of carbon flux (often 30–50%) is diverted toward biomass formation, energy maintenance, and byproduct secretion. The cell-free system redirects 100% of the carbon source toward D-psicose production, dramatically improving theoretical yield.
- Toxicity Tolerance: High concentrations of substrates or products can inhibit or kill living cells. D-psicose itself, along with intermediate substrates like fructose-6-phosphate or high fructose loads, can exert osmotic stress. A cell-free system is agnostic to product toxicity, allowing for much higher final titers—often exceeding 200–300 g/L in optimized runs—without cell lysis concerns.
- Precise Pathway Control: The patents detail the ability to stoichiometrically balance enzyme ratios. In a living cell, enzyme expression levels are dictated by promoter strength, ribosome binding site efficiency, and plasmid copy number—variables that are difficult to tune dynamically. In the cell-free format, the operator adds purified enzymes or crude lysates in exact molar ratios, optimizing flux through the rate-limiting steps instantly.
- Open System Flexibility: The reaction vessel is "open," allowing for the continuous feeding of unstable cofactors or the in situ removal of inhibitory byproducts (e.g., via membrane separation or resin adsorption) during the reaction, a feat impossible in a sealed, living bioreactor.
Novel Enzymatic Pathways and Protein Engineering Claims
A substantial portion of the GreenLight Biosciences D-psicose biosynthesis patent US coverage focuses on the biocatalysts themselves. While the enzyme D-psicose 3-epimerase (DPEase, EC 5.Also, the primary route to D-psicose involves the isomerization of D-fructose. 3.1.30) is the industry standard catalyst, wild-type variants suffer from low thermostability, modest specific activity, and product inhibition The details matter here..
Easier said than done, but still worth knowing.
The patent portfolio claims engineered DPEase variants exhibiting:
- Enhanced Thermostability: Mutations allowing operation at 50–60°C. Higher temperatures reduce viscosity, increase substrate solubility (fructose solubility increases significantly with temperature), and lower contamination risk—critical for industrial runs lasting 24–72 hours.
- Altered Cofactor Independence/Dependence: Engineering enzymes to function optimally with specific metal ions (Mn2+, Co2+) or removing metal dependence entirely to simplify downstream purification and reduce raw material costs.
- Reduced Product Inhibition: Variants with modified active site architectures that lower the binding affinity for D-psicose (the product) while maintaining high affinity for D-fructose (the substrate), pushing the equilibrium conversion closer to the theoretical maximum (approx. 30-35% at standard conditions, higher at elevated temps).
What's more, the patents explore multi-enzyme cascades. The patent claims cover the specific enzyme combinations, the ATP regeneration systems (e.g.One notable pathway described involves the phosphorylation of fructose to fructose-6-phosphate (via a highly active hexokinase or glucokinase variant), followed by isomerization to psicose-3-phosphate (via a phosphoglucose isomerase mutant or a specific psicose-3-phosphate synthase), and finally dephosphorylation by a phosphatase. And while more complex enzymatically, this ATP-driven route can thermodynamically drive conversions higher than the simple isomerization equilibrium allows. , polyphosphate kinase / polyphosphate or acetate kinase / acetyl phosphate), and the specific reaction conditions (pH, ionic strength, crowding agents) that make this cascade economically viable.
Cofactor Regeneration: The Economic Linchpin
Any discussion of biosynthesis patents must address cofactor economics. NADPH and ATP are prohibitively expensive to purchase stoichiometrically for commodity chemical production. The GreenLight Biosciences D-psicose biosynthesis patent US documents place heavy emphasis on integrated cofactor regeneration modules.
For the isomerization route (DPEase), no cofactors are strictly required, but for the phosphorylated cascade, ATP regeneration is mandatory. Practically speaking, pPK efficiently transfers the terminal phosphate to ADP, generating ATP. The byproduct is shorter-chain PolyP, which remains soluble and non-inhibitory. g.The patents claim specific, low-cost regeneration systems:
- Polyphosphate (PolyP) / Polyphosphate Kinase (PPK): PolyP is a cheap, polymeric phosphate source. Even so, * Formate / Formate Dehydrogenase (FDH): For NADPH regeneration (if upstream pathways require it, e. , for a ketose reductase route), formate is an inexpensive substrate, and the byproduct is CO2, which vents harmlessly from the open reactor.
The claims often specify the ratio of regeneration enzyme to pathway enzymes, the concentration of the cofactor "pool" (catalytic amounts of ATP/NADPH), and the feed rates for the regeneration substrates. This level of detail demonstrates a focus on Techno-Economic Analysis (TEA)-driven enzyme engineering—optimizing not just for kcat/Km, but for $/kg of product Not complicated — just consistent..
Downstream Processing: Resolving the Separation Bottleneck
A recurring theme in the GreenLight Biosciences D-psicose biosynthesis patent US portfolio is the acknowledgment that reaction engineering is only half the battle; the separation of D-psicose from unreacted D-fructose represents the dominant capital and operating expenditure (CAPEX/OPEX) in the process. Because the two sugars share nearly identical molecular weights (180.16 g/mol), polarity, and solubility profiles, traditional crystallization or distillation are ineffective or energy-prohibitive at scale.
The patents claim several innovative separation strategies integrated directly into the bioprocess design:
- Simulated Moving Bed (SMB) Chromatography Optimization: Rather than claiming SMB generically, the patents specify tailored stationary phases (e.g., calcium-loaded cation exchange resins vs. boronate-affinity ligands) and, critically, the feed concentration and desorbent (water/ethanol) gradients optimized for the specific impurity profile of the enzymatic broth (salts, buffer components, trace proteins). Claims cover the "heart-cut" collection strategy that maximizes psicose purity (>99.5%) while recycling the fructose-rich raffinate directly back to the reactor inlet, creating a true closed-loop continuous process.
- In-Situ Product Removal (ISPR) via Boronate Affinity: Several claims describe reactors incorporating phenylboronic acid-functionalized resins or membranes within the reaction vessel (or in a side-stream loop). These materials form reversible covalent esters with the cis-diol groups of psicose (and fructose) at alkaline pH, but the binding kinetics and elution profiles differ sufficiently to allow selective psicose capture. By continuously removing psicose as it forms, ISPR simultaneously drives the equilibrium-limited isomerization forward (Le Chatelier’s principle) and simplifies downstream purification. The patents claim specific pH-swing elution protocols using dilute acid or competitive sugars (e.g., sorbitol) that regenerate the resin without denaturing the co-localized enzymes.
- Membrane-Based Fractionation: For the phosphorylated cascade, the patents claim nanofiltration (NF) diafiltration trains operated at specific molecular weight cut-offs (MWCO 150–300 Da) to separate the product (psicose/psicose-3-phosphate) from the high-MW enzymes and the regeneration polymer (PolyP). This allows for enzyme retention and reuse over extended campaigns (targeting >30 days continuous operation), drastically reducing the enzyme production cost contribution per kg of product.
Biocatalyst Formulation & Stability: From Lab to Plant
The transition from a purified enzyme in a buffered cuvette to a dependable industrial biocatalyst is heavily patented. The GreenLight Biosciences D-psicose biosynthesis patent US filings detail formulation compositions that confer stability against the harsh realities of industrial fructose syrups (high solids >50% w/v, elevated temperature 50–65°C, trace metal ions, shear stress).
Key claimed innovations include:
- Cross-Linked Enzyme Aggregates (CLEAs) & Combi-CLEAs: Co-aggregation of the pathway enzymes (e.Plus, g. , DPEase + Hexokinase + PPK) with a bovine serum albumin (BSA) or soy protein carrier, cross-linked with glutaraldehyde. Claims specify the protein-to-enzyme ratio and precipitant type (ammonium sulfate vs. Because of that, tert-butanol) that maximize specific activity retention (>80%) while imparting mechanical rigidity for packed-bed reactor operation. Worth adding: * Solid Supports with Oriented Immobilization: Covalent attachment via engineered C-terminal SpyTag/SpyCatcher pairs or His-tag/Ni-NTA silica supports. Which means the patents claim the specific linker chemistry (e. Consider this: g. , PEG spacers of defined length) that minimizes steric hindrance for the bulky fructose substrate while preventing enzyme leaching under high substrate viscosity.
- Stabilizing Additive Cocktails: Proprietary formulations comprising polyols (glycerol, sorbitol), non-ionic surfactants (Tween 80, Triton X-100), and specific divalent cation chelators (EDTA analogs) that prevent thermal aggregation and metal-catalyzed oxidation of surface methionine residues identified via peptide mapping as degradation hotspots.
Host Engineering & "Cell-Free" vs. "Whole Cell" Trade-offs
The portfolio strategically protects both production modalities. For in vivo whole-cell biocatalysis (using engineered E. coli, Corynebacterium glutamicum, or Bacillus subtilis), claims cover:
- Genomic integration cassettes knocking out native fructose/psicose catabolic pathways (fruB, psl, aga operons) and phosphotransferase system (PTS) components to prevent substrate consumption and carbon catabolite repression.
